Back to Journals » Cancer Management and Research » Volume 11

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

Authors Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A

Received 21 February 2019

Accepted for publication 21 June 2019

Published 8 August 2019 Volume 2019:11 Pages 7537—7556


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Chien-Feng Li

Cristina Saavedra,1,2 Jorge Barriuso,1,3 Mairéad G McNamara,1,3 Juan W Valle,1,3 Angela Lamarca1,3

1Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; 2Medical Oncology Department, Ramon Y Cajal University Hospital, Madrid, Spain; 3Division of Cancer Sciences, University of Manchester, Manchester, UK

Abstract: Neuroendocrine tumors (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with carcinoid syndrome symptoms, characterized by diarrhea, flushing and/or wheezing. This review summarizes the current treatment options for carcinoid syndrome, focusing on the latest novel treatment option, telotristat ethyl. In addition, information on patient-reported outcomes and impact of carcinoid syndrome on quality of life (QOL) and improvement of following treatment with telotristat ethyl are reviewed. This article also provides an overview of the current QOL questionnaires for patients with NETs and addresses unmet needs in this field of patient-reported outcomes.

Keywords: telotristat ethyl, carcinoid syndrome, NET, diarrhea

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]